Purpose: This study compared clinical outcomes and complications between 23-gauge (23g) and 25-gauge (25g) transconjunctival sutureless vitrectomy in patients with proliferative diabetic retinopathy. Study Design: It was a retrospective study using data prospectively defined and collected. 80 eyes underwent 23g transconjunctival sutureless vitrectomy, and 80 eyes underwent 25g surgery using the same vitrectomy system by one surgeon. Primary outcome measures were best-corrected visual acuity, intraocular pressure (IOP), and incidence of intraoperative and postoperative complications. Results: Vision was significantly improved after intervention in both groups (p ≥ 0.0001). There was no significant difference in visual outcomes between the groups (p = 0.43) or in the type and frequency of retinal breaks occurring during surgery (p = 0.63). The 23g group had significantly more patients with a day 1 IOP of <6 mm Hg (p = 0.034) and significantly more patients requiring a sclerostomy suture postoperatively (p = 0.014). Conclusion and Message: Both gauges are equally effective for the treatment of proliferative diabetic retinopathy.

1.
Fujii GY, De Juan E Jr, Humayun MS, Chang TS, Pieramici DJ, Barnes A, et al: Initial experience using the transconjunctival sutureless vitrectomy system for vitreoretinal surgery. Ophthalmology 2002;109:1814-1820.
2.
Sato T, Emi K, Bando H, Ikeda T: Faster recovery after 25-gauge microincision vitrectomy surgery than after 20-gauge vitrectomy in patients with proliferative diabetic retinopathy. Clin Ophthalmol 2012;6:1925-1930.
3.
Nagpal M, Wartikar S, Nagpal K: Comparison of clinical outcomes and wound dynamics of sclerotomy ports of 20, 25, and 23 gauge vitrectomy. Retina 2009;29:225-231.
4.
American Society of Retina Specialists. https://www.asrs.org/content/documents/_2013asrspatsurveyresults.pdf (accessed February 19, 2014).
5.
Erakgun T, Egrilmez S: Surgical outcomes of transconjunctival sutureless 23-gauge vitrectomy with silicone oil injection. Indian J Ophthalmol 2009;57:105-109.
6.
Bourla DH, Bor E, Axer-Siegel R, Mimouni K, Weinberger D: Outcomes and complications of rhegmatogenous retinal detachment repair with selective sutureless 25-gauge pars plana vitrectomy. Am J Ophthalmol 2010;149:630-634.
7.
Ozone D, Hirano Y, Ueda J, Yasukawa T, Yoshida M, Ogura Y: Outcomes and complications of 25-gauge transconjunctival sutureless vitrectomy for proliferative diabetic retinopathy. Ophthalmologica 2011;226:76-80.
8.
Singh R, Kumari N, Katoch D, Sanghi G, Gupta A, Dogra MR: Outcome of 23-gauge pars plana vitrectomy for pediatric vitreoretinal conditions. J Pediatr Ophthalmol Strabismus 2014;51:27-31.
9.
Krishnan R, Tossounis C, Fung Yang Y: 20-gauge and 23-gauge phacovitrectomy for idiopathic macular holes: comparison of complications and long-term outcomes. Eye (Lond) 2013;27:72-77.
10.
Lewis SA, Miller DM, Riemann CD, Foster RE, Petersen MR: Comparison of 20-, 23-, and 25-gauge pars plana vitrectomy in pseudophakic rhegmatogenous retinal detachment repair. Ophthalmic Surg Lasers Imaging 2011;42:107-113.
11.
Von Fricken MA, Kunjukunju N, Weber C, Ko G: 25-Gauge sutureless vitrectomy versus 20-gauge vitrectomy for the repair of primary rhegmatogenous retinal detachment. Retina 2009;29:444-450.
12.
Cha DM, Woo SJ, Park KH, Chung H: Intraoperative iatrogenic peripheral retinal break in 23-gauge transconjunctival sutureless vitrectomy versus 20-gauge conventional vitrectomy. Graefes Arch Clin Exp Ophthalmol 2013;251:1469-1474.
13.
Neuhann IM, Hilgers RD, Bartz-Schmidt KU: Intraoperative retinal break formation in 23-/25-gauge vitrectomy versus 20-gauge vitrectomy. Ophthalmologica 2013;229:50-53.
14.
Dugel PU, Zhou J, Abulon DJ, Buboltz DC: Tissue attraction associated with 20-gauge, 23-gauge, and enhanced 25-gauge dual-pneumatic vitrectomy probes. Retina 2012;32:1761-1766.
15.
Oshima Y, Wakabayashi T, Sato T, Ohji M, Tano Y: A 27-gauge instrument system for transconjunctival sutureless microincision vitrectomy surgery. Ophthalmology 2010;117:93-102.
16.
Early Treatment Diabetic Retinopathy Study Research Group: Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Ophthalmology 1987;94:761-774.
17.
Yorston D, Wickham L, Benson S, Bunce C, Sheard R, Charteris D: Predictive clinical features and outcomes of vitrectomy for proliferative diabetic retinopathy. Br J Ophthalmol 2008;92:365-368.
18.
Steel DH, Charles S: Vitrectomy fluidics. Ophthalmologica 2011;226(suppl 1):27-35.
19.
Diabetic Retinopathy Vitrectomy Study Group: Two year course of visual acuity in severe proliferative diabetic retinopathy with conventional management. Diabetic Retinopathy Vitrectomy Study (DRVS) Report No 1. Ophthalmology 1985;92:492-502.
20.
Holladay JT: Visual acuity measurements. J Cataract Refract Surg 2004;30:287-290.
21.
Park DH, Shin JP, Kim SY: Comparison of clinical outcomes between 23-gauge and 20-gauge vitrectomy in patients with proliferative diabetic retinopathy. Retina 2010;30:1662-1670.
22.
Akçay B, Uyar OM, Akkan F, Eltutar K: Outcomes of 23-gauge pars plana vitrectomy in vitreoretinal diseases. Clin Ophthalmol 2011;5:1771-1776.
23.
Lott MN, Manning MH, Singh J, Zhang H, Singh H, Marcus DM: 23-Gauge vitrectomy in 100 eyes: short-term visual outcomes and complications. Retina 2008;28:1193-1200.
24.
Framme C, Klotz S, Wolf-Schnurrbusch UE, Wiedemann P, Wolf S: Intraocular pressure changes following 20G pars-plana vitrectomy. Acta Ophthalmol 2012;90:744-749.
25.
Gupta OP, Weichel ED, Regillo CD, Fineman MS, Kaiser RS, Ho AC, McNamara JA, Vander JE: Postoperative complications associated with 25-gauge pars plana vitrectomy. Ophthalmic Surg Lasers Imaging 2007;38:270-275.
26.
Yang SJ, Yoon SY, Kim JG, Yoon YH: Transconjunctival sutureless vitrectomy for the treatment of vitreoretinal complications in patients with diabetes mellitus. Ophthalmic Surg Lasers Imaging 2009;40:461-466.
27.
Farouk MM, Naito T, Sayed KM, Nagasawa T, Katome T, Radwan G, Abdallah A, Elagouz M: Outcomes of 25-gauge vitrectomy for proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2011;249:369-376.
28.
Schoenberger SD, Miller DM, Riemann CD, Foster RE, Sisk RA, Hutchins RK, Petersen MR: Outcomes of 25-gauge pars plana vitrectomy in the surgical management of proliferative diabetic retinopathy. Ophthalmic Surg Lasers Imaging 2011;42:474-480.
29.
Issa SA, Connor A, Habib M, Steel DH: Comparison of retinal breaks observed during 23 gauge transconjunctival vitrectomy versus conventional 20 gauge surgery for proliferative diabetic retinopathy. Clin Ophthalmol 2011;20:109-114.
30.
Scott IU, Flynn HW Jr, Dev S, et al: Endophthalmitis after 25-gauge and 20-gauge pars plana vitrectomy: incidence and outcomes. Retina 2008;28:138-142.
31.
Wu L, Berrocal MH, Arévalo JF, Carpentier C, Rodriguez FJ, Alezzandrini A, Farah ME, Roca JA, Maia M, Saravia M, Morales-Cantón V, Graue-Wiechers F, Cardillo JA: Endophthalmitis after pars plana vitrectomy: results of the Pan American Collaborative Retina Study Group. Retina 2011;31:673-678.
32.
Park JC, Ramasamy B, Shaw S, Prasad S, Ling RH: A prospective and nationwide study investigating endophthalmitis following pars plana vitrectomy: incidence and risk factors. Br J Ophthalmol 2014;98:529-533.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.